Cohort Study: Antibody Responses to Ebola Vaccine are Sustained for at Least 2 Years
17 Apr, 2018 | 20:00h | UTCDeterminants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study – The Lancet Infectious Diseases (link to abstract – $ for full-text)
Commentary: In encouraging sign, Ebola vaccine appears to provide long-lasting protection – STAT (free)